Donanemab is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Alzheimer’s Disease. According to GlobalData, Pre-Registration drugs for Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Donanemab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Donanemab overview
Donanemab (LY-3002813) is under development for the treatment of early symptomatic Alzheimer's disease. It is administered intravenously and subcutaneously. LY-3002813 is a monoclonal antibody that acts by targeting N3pG beta-amyloid (amyloid precursor protein). The drug candidate is a new biological entity (NBE).
For a complete picture of Donanemab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.